Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Liabilities and Shareholders Equity: 2019-2024

Historic Liabilities and Shareholders Equity for Revolution Medicines (RVMD) over the last 6 years, with Dec 2024 value amounting to $2.6 billion.

  • Revolution Medicines' Liabilities and Shareholders Equity rose 27.73% to $2.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.6 billion, marking a year-over-year increase of 27.36%. This contributed to the annual value of $2.6 billion for FY2024, which is 24.09% up from last year.
  • Latest data reveals that Revolution Medicines reported Liabilities and Shareholders Equity of $2.6 billion as of FY2024, which was up 24.09% from $2.1 billion recorded in FY2023.
  • In the past 5 years, Revolution Medicines' Liabilities and Shareholders Equity ranged from a high of $2.6 billion in FY2024 and a low of $567.4 million during FY2020.
  • Its 3-year average for Liabilities and Shareholders Equity is $1.8 billion, with a median of $2.1 billion in 2023.
  • Data for Revolution Medicines' Liabilities and Shareholders Equity shows a peak YoY skyrocketed of 157.29% (in 2020) over the last 5 years.
  • Over the past 5 years, Revolution Medicines' Liabilities and Shareholders Equity (Yearly) stood at $567.4 million in 2020, then skyrocketed by 30.06% to $738.0 million in 2021, then grew by 10.02% to $811.9 million in 2022, then surged by 153.93% to $2.1 billion in 2023, then increased by 24.09% to $2.6 billion in 2024.